Headquartered in West Conshohocken, PA Fiscal year ends December NASDAQ: MDGL madrigalpharma.com
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, liver cancer, and the need for liver transplantation. The company's commercial product, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor-beta (THR-β) agonist designed to target key underlying causes of MASH. Rezdiffra was approved by the FDA and the European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). The company is also developing MGL-2086, an oral GLP-1 receptor agonist, as a potential combination therapy with Rezdiffra. As of mid-2026, more than 50,000 patients are actively being treated with Rezdiffra, and the product has generated nearly $1.3 billion in trailing-12-month net sales. Updated
Wall Street wasted no time Monday, sending the Nasdaq surging past 25,900 while analysts took aim at some of the market's biggest names with fresh upgrades, downgrades, and new coverage that could…
Artificial intelligence has dominated investor attention for two years, but biotech revenue lines are also bending sharply higher. A small group of biotechs is building real commercial businesses around recently approved drugs,…
Insiders continue to scoop up Under Armour and W.R. Berkley shares, and a public offering of International Tower Hill Mines shares prompted huge insider purchases as well.
The past week's most notable insider buying included a biopharmaceutical company, a pipeline company, and an industrial products maker.
Market pullbacks can make nervous investors leery of investing in industries that are more speculative. Wall Street still has big expectations for Viking Therapeutics.
John Paulson is among the most well-known billionaires, famous for his long-term investing returns via his hedge fund Paulson & Co. The hedge fund manager has concentrated his portfolio in interesting stocks,…
Chris MacDonald The best investment billionaire John Paulson ever made was a bet against something. He famously predicted the collapse of the U.S. housing market and made a $20 billion profit doing so. Today,…
Warren Buffett's Berkshire Hathaway has bolstered its stake in Occidental Petroleum with a huge purchase of shares. Insider buying is heating up in general.
Some of the biggest insider buying since the Thanksgiving holiday has come from repeat buyers, including Bill Ackman, who continues to build his stake in a real estate firm.
Notable insider buying in the past week included biotech and energy companies, including some that have just gone public. Also, renowned hedge fund manager Bill Ackman continues building a stake in a…
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, liver cancer, and the need for liver transplantation.
24/7 Wall St.'s 12-month price target for MDGL is $807.62, rated Buy. The Wall Street consensus target is $682.11. MDGL price prediction →
